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OBJECTIVE: The present study was designed to analyze the serum levels of aspartate and alanine aminotransferases,
gamma-glutamyl transferase, and the hematocrit in patients with chronic kidney disease who were undergoing
peritoneal dialysis or hemodialysis.
PATIENTS AND METHODS: Twenty patients on peritoneal dialysis and 40 on hemodialysis were assessed, and the
patients were matched according to the length of time that they had been on dialysis. Blood samples were
collected (both before and after the session for those on hemodialysis) to measure the enzymes and the
hematocrit.
RESULTS: In the samples from the patients who were undergoing peritoneal dialysis, the aspartate and alanine
aminotransferase levels were slightly higher compared with the samples collected from the patients before the
hemodialysis session and slightly lower compared with the samples collected after the hemodialysis session. The
levels of gamma-glutamyl transferase in the hemodialysis patients were slightly higher than the levels in the
patients who were undergoing peritoneal dialysis. In addition, the levels of aminotransferases and gamma-glutamyl
transferase that were collected before the hemodialysis session were significantly lower than the values collected
after the session. The hematocrit levels were significantly lower in the patients who were on peritoneal dialysis
compared with the patients on hemodialysis (both before and after the hemodialysis session), and the levels were
also significantly lower before hemodialysis compared with after hemodialysis.
CONCLUSION: The aminotransferase levels in the patients who were undergoing peritoneal dialysis were slightly
higher compared with the samples collected before the hemodialysis session, whereas the aminotransferase levels
were slightly lower compared with the samples collected after the session. The hematocrits and the
aminotransferase and gamma-glutamyl transferase levels of the samples collected after the hemodialysis session
were significantly higher than the samples collected before the session. Taken together, the present data suggest
that hemodilution could alter the serum levels of liver enzymes.
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INTRODUCTION
Patients with chronic kidney disease (CKD) who are
undergoing hemodialysis (HD) and are infected with
hepatitis C virus (HCV) have been shown to present with
lower serum levels of alanine aminotransferase (ALT) than
HCV-infected patients with normal renal function (1,2).
Generally, ALT levels are below the upper limit of the
normal (ULN) range but higher than the levels found in
noninfected HD patients (3-5).
Even in noninfected HCV patients, ALT serum levels are
lower in patients with CKD undergoing HD compared with
the population that has normal renal function (6,7). ALT
levels may be lower because of a deficiency in vitamin B6,
which is a coenzyme of ALT, or hemodilution, which occurs
because of water retention in patients with CKD before an
HD session (8-10).
In regard to patients who do not have CKD, there has
been a proposal to reduce the ULN of ALT to approximately
70% of the ‘‘conventional limits’’ when screening for liver
abnormalities. Clinicians have argued that the current
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131limits, which were originally defined approximately 25
years ago, may consider some individuals to be ‘‘healthy’’
when they actually have steatosis or an HCV infection.
When the ULN was reduced, there was an increase in the
sensitivity of ALT from 55% to 76% for the diagnosis of
‘‘discrete’’ liver diseases; however, the specificity was
reduced from 97% to 89% (11). A study of a large Korean
population revealed that the risk of mortality from liver
disease would be higher in individuals with normal levels
of ALT that were close to the ULN compared with
individuals with lower ALT levels. A proposal was put
forward to reduce the ULN level to approximately 75% of
the current ULN level of ALT (12).
In an attempt to clarify whether lower levels of
aminotransferases in patients with CKD are a result of
renal failure or the type of dialysis treatment, the present
preliminary study analyzed the ALT serum levels in
patients who were undergoing peritoneal dialysis (PD)
and HD. We also measured the levels of aspartate
aminotransferase (AST) and gamma-glutamyl transferase
(GGT). In addition, the hematocrit (Ht) was assessed to
investigate the possibility of hemodilution.
PATIENTS AND METHODS
The present study, which was conducted as a case series
with an internal comparison group, involved 60 patients
with CKD who were in renal replacement therapy and
attended a dialysis unit in the city of Recife, Brazil. Twenty
of the 26 patients who were undergoing PD were included;
six were excluded because they either refused to take part in
the study or switched their type of dialysis. Concurrently, 40
out of the 211 patients who were undergoing HD in the
Nefroclinica Dialysis Unit were randomly selected for the
present study, and the HD patients were paired in a 152
ratio according to the period of time that they had been on
renal replacement therapy.
To be included in the present study, patients had to be at
least 18 years old, have CKD, and have been undergoing
dialysis therapy by HD or PD for a minimum of six months.
The patients were excluded if they had previously been
diagnosed with hepatitis B and/or if they consumed $40 g/
day of alcohol.
After explaining the aims of the study to the patients,
interviews were conducted by a researcher (IROL), and
blood samples were collected and sent to the Central
Laboratory at the Hospital das Clı ´nicas – Universidade
Federal de Pernambuco.
ALT, AST, and GGT serum levels were determined by an
automated kinetic method for blood samples, which were
taken from each patient immediately before and after a
single HD session. In addition, samples were obtained from
the patients who were undergoing PD after they completed
the questionnaire.
The serum concentration for each patient was divided by
the ULN (according to gender) of ALT (31 IU/L for women
and 41 IU/L for men), AST (31 IU/L for women and 35 IU/
L for men), and GGT (38 IU/L for women and 55 IU/L for
men). The Ht was measured using a CELL-DYN 4000
analyzer. Antibodies (anti-HCV) against the HCV and
surface antigen (HBsAg) of hepatitis B virus (HBV) were
determined by enzyme immunoassays (AbbottH).
We compared the Ht and the median serum levels of AST,
ALT, and GGT in the patients on PD with the values from
the patients on HD before and after the dialysis session. In
addition, we compared the Ht and the median serum levels
of the enzymes in the 40 patients who were undergoing HD
before and after the dialysis session. Excel software was
used, and the Mann-Whitney U test was applied to compare
the median (P25;P 75) values. The chi-squared test or Fisher’s
exact test was used to compare frequencies, and statistical
significance was set as p,0.05.
The study was approved by the Ethics Committee of the
Health Sciences Center at the Universidade Federal de
Pernambuco and followed the guidelines established by the
Declaration of Helsinki.
RESULTS
Table 1 provides a description of the demographic
characteristics, the occurrence of anti-HCV and the etiology
of CKD in the 60 patients who were included in the present
study (the patients were divided into two groups according
to the type of dialysis). Among the 20 PD patients, 12 (60%)
had received HD before beginning the PD treatment. In
these 20 PD patients, the AST and ALT serum levels were
each higher than the ULN in three patients (15% for each
enzyme). In addition, the GGT levels in eight patients (40%)
were higher than the ULN.
Among the 40 HD patients, the AST serum level was
higher than the ULN in two (5%) patients before the dialysis
session and three patients (7.5%) after the dialysis session,
and similar findings were observed for the levels of ALT
(i.e., the ALT serum level was higher in three (7.5%) patients
before dialysis and five (12.5%) patients postdialysis). The
GGT serum level was higher than the ULN in 17 (42.5%)
patients before dialysis and 21 (52.5%) patients postdialysis.
Table 2 provides a description of the median Ht in the 60
patients with CKD and the median values and ranges of the
AST, ALT, and GGT serum levels divided by the ULN. It
should be emphasized that the median values of the serum
levels of the aminotransferases were below the ULN in the
patients who were undergoing PD and HD (both before and
after the session). The median values of GGT were near the
Table 1 - Demographic characteristics and etiologies of
chronic renal failure for the 60 patients who were
undergoing dialysis (20 on PD and 40 on HD).
Peritoneal
dialysis Hemodialysis p-value
N 20 40
Age¡SD (years)
Range (years)
48¡17
(24 - 78)
54¡15
(21 - 86)
0.168
Female (%) 11 (55%) 20 (50%) 0.927
Anti-HCV+ 3 (15%) 3 (7.5%)
Etiology of chronic renal
failure
Systemic arterial
hypertension
3 (15%) 12 (30%) 0.343
Diabetes mellitus 3 (15%) 4 (10%) 0.676
SAH + DM 0 (0%) 2 (5%) 0.548
Systemic lupus
erythematosus
3 (15%) 2 (5%) 0.322
Others 1 (5%) 10 (25%) 0.081
Undetermined 10 (50%) 10 (25%) 0.100
anti-HCV – hepatitis C virus antibody; SAH – systemic arterial
hypertension;
DM – diabetes mellitus.
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132ULN in patients on PD and in samples collected before the
HD session; however, they were higher than the ULN in the
samples collected after the HD session (Figure 1).
In the patients who were undergoing PD, the median AST
(0.53 IU/L) and ALT (0.39 IU/L) serum levels were slightly
higher compared with the samples collected from the HD
patients before their HD session (0.47 and 0.37 IU/L,
respectively) and slightly lower than samples collected after
the session (0.68 and 0.44 IU/L, respectively). The GGT
serum levels were slightly lower in the patients who were
undergoing PD compared with the samples collected from
the patients who were undergoing HD (both before and
after the session).
We also analyzed the median Ht and the median AST, ALT,
and GGT serum levels divided by the ULN before and after
dialysis for the 40 patients with CKD who were undergoing
HD. The AST, ALT, and GGT serum levels that were collected
before the dialysis session were significantly lower than the
values that were observed after dialysis (Table 2).
The Ht rates were significantly lower in the patients on
PD compared with the patients on HD (both before and
after the session), and the Ht rates were also significantly
lower before dialysis compared with after the HD session
(Table 2).
DISCUSSION
Studies have revealed that ALT serum levels are lower in
patients with CKD compared with patients with normal
renal function, which raises the question of whether the
lower levels are related to CKD factors or to the HD
treatment (1,2,10,13-15).
Researchers have assumed that there is a correlation
between the ALT serum levels and the severity of renal
failure caused by glomerular lesions. Indeed, Fabrizi et al. (8)
reported lower ALT levels in patients who were undergoing
HDcompared with patientswithCKDwhowere undergoing
conservative treatment (predialysis), which demonstrated
that the ALT serum levels were reduced concomitantly with
the progression of renal dysfunction.
Nevertheless, given the possibility that hypoaminotrans-
ferasemia could be related to hemodilution, the present
preliminary study assessed patients who were undergoing
HD and patients who were undergoing PD. We observed
that the ALT serum levels were slightly higher in the 20
patients with CKD who were undergoing PD compared
with the 40 patients who were undergoing HD when the
samples were collected before the dialysis session. A
comparison of the mean ALT serum levels for the patients
on PD and the postdialysis measurements for the HD
patients showed that the ALT levels after therapy were
slightly higher. These findings suggest that hemodilution
could be involved in reducing ALT levels. Interestingly, the
patients on HD presented with fluid retention before the
dialysis session; however, the fluid retention regressed after
the session ended. If the present study included a larger
number of patients, the differences in the median values of
aminotransferases may have been even greater.
Indeed, a recent study has confirmed that the Ht and the
ALT level are lower before HD and higher after dialysis,
which is inversely proportional to the loss of water weight
(10). The patients on PD, however, did not present with
fluid accumulation or rapid fluid loss, which normally
occurs after HD sessions. In addition, the patients on PD
evolved with stable and higher serum levels of aminotrans-
ferases.
Table 2 - The median (P25;P 75) Ht and the median serum levels of AST, ALT, and GGT divided by the ULN for the 20
patients on PD compared with the 40 patients on HD (before and after the HD session).
Liver
enzymes
Peritoneal
dialysis
Median (P25;P 75)
Before
hemodialysis
Median (P25;P 75) p-value
After
hemodialysis
Median (P25;P 75) p-value
AST/ULN
(range IU/L)
0.53 (0.41; 0.61)
(4 – 121)
0.47 (0.41; 0.55)
a
(8 – 93)
0.54 0.68 (0.46; 0.77)
a
(3 – 48)
0.13
ALT/ULN
(range IU/L)
0.39 (0.22; 0.71)
(6 – 125)
0.37 (0.21; 0.56)
b
(6 – 66)
0.87 0.44 (0.27; 0.77)
b
(6 – 87)
0.42
GGT/ULN
(range IU/L)
0.83 (0.55; 1.48)
(13 – 155)
0.88 (0.43; 1.55)
c
(9 – 318)
0.74 1.14 (0.51; 2.10)
c
(4 – 372)
0.68
Ht (%) 32.9 (29.8; 35.5) 36.7 (32.1; 41.3)
d 0.03 41.3 (33.1; 47.1)
d 0.001
a) p,0.001 b) p,0.001 c) p,0.001 d) p,0.001.
AST – aspartate aminotransferase; ALT – alanine aminotransferase;
GGT – gamma-glutamyl transferase; Ht – hematocrit;
ULN – upper limit of normal.
Figure 1 - Median (P25;P 75), minimum and maximum values of
the serum levels of AST, ALT, and GGT divided by the ULN for the
20 patients on PD and the 40 patients on HD (before and after
the HD session).
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133The possibility of hemodilution is corroborated when the
mean values of AST and ALT in the same 40 patients are
compared in the samples collected before and after the HD
session. There was a significant increase in both the AST
and the ALT serum levels after the dialysis session.
Moreover, a significant increase in the Ht after the HD
session was also observed, which provided support for the
hypothesis that patients with CKD retain water before HD.
Few authors have discussed AST and GGT levels in
patients with CKD who were undergoing dialysis treatment
(4). The data from the present study illustrated that AST and
GGT levels behave in a similar manner as ALT, which
excludes the possibility of an alteration in aminotransferase
production, such as a reduction of synthesis because of
vitamin B6 deficiency (9).
Importantly, the GGT levels exceeded the ULN in the
two groups of patients with a greater frequency than
the aminotransferases. Furthermore, the median values of
the GGT serum levels were near the ULN and were higher
than those for AST and ALT in the three measurements.
Similarly, Souza et al. evaluated 87 patients with CKD and
observed that the GGT serum levels were higher than the
aminotransferase levels (16).
The high GGT levels in patients who were undergoing
dialysis may have been induced by the use of medication or
been related to the origins of CKD, such as diabetes
mellitus, which can cause steatohepatitis (17). In addition,
high GGT serum levels could be related to malnutrition-
inflammation-atherosclerosis (MIA syndrome), which has
been observed in patients with CKD who were undergoing
dialysis because of systemic arterial hypertension or
diabetes mellitus (18).
There are only a few articles, however, that describe the
GGT levels in patients with CKD (16,19,20), and further
studies are needed to assess the possibility of other
mechanisms that may be involved in the changes of this
liver enzyme.
Unlike the aminotransferases, the Ht was lower in the
patients onPD comparedwith the patients on HD(both before
and after the HD session). This finding could be related to the
improved control of anemia in patients on HD and to the more
appropriate replacement of iron supplementation and ery-
thropoietin because the patients on HD have more frequent
contact with the dialysis unit than the patients on PD.
In conclusion, the aminotransferase serum levels were
slightly higherin the patients with CKD whowere undergoing
PDcompared with the patients on HDwhen the sampleswere
collectedbeforetheHDsession.Inaddition,themedianvalues
ofthe samples collected after the HD session were significantly
higher than the values collected before dialysis. Because this
was the first study to analyze these three enzymes in patients
on HD and patients on PD, further research is needed to
confirm whether hemodilution is the cause of these differences
or whether other factors are involved in the alteration of the
AST, ALT and GGT serum levels.
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